Health Trials

Clinical trials

9

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study

A Single-Center, Open-Label, Single-Arm Exploratory Clinical Study on the Use of Autologous CAR-T Cell Therapy Injection for the Treatment of Refractory and Relapsing Ulcerative Colitis: A Preliminary Exploration of 12-Week Clinical Remission with Autologous CAR-T Cell Injection in Refractory and Relapsing Ulcerative Colitis.

Participants needed: 12
Trial details
Phase: Early Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Feb 27, 2026Locations: 1
Eligibility criteria

The subject or guardian must provide voluntary informed consent; [+4]

Women who are pregnant or lactating; [+9]

Read more
Status: Not yet recruiting

Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.

To Evaluate Safety and Efficacy of S103 for Treating Relapsed or Refractory Multiple Myeloma

Participants needed: 24
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Feb 19, 2026
Eligibility criteria

Bone marrow cytology, bone marrow biopsy tissue, or flow cytometry showing ≥5% c... [+3]

QTc interval >470 ms (QTc interval corrected using the Fridericia formula); [+4]

Read more
Status: Recruiting

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.

Participants needed: 59
Trial details
Phase: Phase 2Age: 3-25Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Nov 24, 2025Locations: 1
Eligibility criteria

1.Sign the informed consent and be willing and able to comply with the visit, tr...

1.Relapse of isolated extramedullary disease; 2.Burkitt lymphoma/leukemia； 3.Act...

Read more
Status: Not yet recruiting

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.

Participants needed: 38
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Nov 24, 2025
Eligibility criteria

1.The subject or guardian must provide voluntary informed consent; 2.Heavily pre...

1.Patients with a history of allogeneic hematopoietic stem cell transplantation...

Read more
Status: Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases

Participants needed: 30
Trial details
Phase: Phase 1, Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Sep 8, 2025Locations: 1
Eligibility criteria

1.Refractory Moderate-to-Severe Systemic lupus erythematosus (SLE) 1.1.Age 18-70... [+3]

(1) Clinically significant (as determined by the investigator) history of cardia...

Read more
Status: Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.

Participants needed: 50
Trial details
Age: 14-75Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Jun 24, 2025Locations: 1
Eligibility criteria

Sign the informed consent and be willing and able to comply with the visit, trea... [+13]

Severe cardiac insufficiency; [+10]

Read more
Status: Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

To observe the long-term efficacy and safety of dual-target chimeric antigen receptor T cells in the treatment of refractory relapsed B cell hematologic tumors (at least 2 years).

Participants needed: 100
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Jun 18, 2025Locations: 1
Eligibility criteria

Refractory and relapsed B-cell tumor determined by clinical diagnosis, B cell tu... [+1]

With other diseases that are not effectively controlled, including, but not limi... [+9]

Read more
Status: Recruiting

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory T-LBL/ALL.

Participants needed: 9
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Nov 18, 2023Locations: 1
Eligibility criteria

relapse: Primordial cells (>5%)in peripheral blood or bone marrow appeared again... [+16]

New York Heart Association (NYHA) classification ≥ grade III heart failure or my... [+13]

Read more
Status: Recruiting

Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL

This is an open, prospective, dose-escalation clinical study to evaluate the safety and efficacy of Senl-T7 in patients with relapsed or refractory CD7+ acute T lymphoblastic leukemia or T lymphoblastic lymphoma.Meanwhile, PK/PD indexes of Senl-T7 were collected.

Participants needed: 100
Trial details
Age: 2-70Biological sex: AllType: InterventionalSponsor: Hebei Senlang Biotechnology Inc., Ltd.Updated: Nov 25, 2022Locations: 1
Eligibility criteria

Diagnosis of relapsed/refractory T-cell lymphoblastic leukemia or T-cell lymphob... [+9]

Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial i... [+13]

Read more